EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Ascletis Pharma Inc (1672) fair value: what the stock is really worth

We calculate from audited financials what Ascletis Pharma Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · HK · ISIN KYG0520K1094

AP Thin data Sep 13, 2026

Ascletis Pharma Inc

1672 · HK

Weakest SetupStrongly overvalued and low quality.

!Fair value HK$1.68 · Strongly overvalued (−80%)
!Quality 49/100
!Weak Growth (revenue 5y −43.4 %/yr)
!negative free cash flow
!Trails peers (2/6)
!Narrow moat 0/100
!Evidence only low, so the estimate is less certain
Watch Ascletis Pharma Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$19.15 HK$0.7800 Fair Value HK$1.68 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range HK$0.7800 – HK$19.15 · fair‑value band HK$1.11 – HK$2.10 · the HK$8.24 price screens above the HK$1.68 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus.

Show more

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.

Stock analysis

Ascletis Pharma Inc (1672) currently trades at HK$8.24, while our model-based Fair Value estimate is HK$1.68, implying the stock looks roughly 390.4% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: HK$1.11 (bear) to HK$2.10 (bull), the price of HK$8.24 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Ascletis Pharma Inc reported revenue of 2.0M CNY in FY2025 versus 76.9M CNY in FY2021, a compound −59.7%/yr. Reported net income was −360M CNY in FY2025.

Key figures

Market cap HK$11.5B (≈ $1.5B) · EPS (TTM) HK$−0.0900 · Return on equity −18.5% · Return on assets (EBIT) −14.1% · Operating margin −31,064% · Revenue (TTM) HK$2.0M · Revenue growth (YoY) −26.2% · Free cash flow −HK$331M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −80%, 1672 screens richer than that median.

Fair Value models

Bear HK$1.11 Fair Value HK$1.68 Bull HK$2.10
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) HK$0.9200 HK$1.23 HK$1.84 51
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.9200 HK$1.23 HK$1.84 51

Open the full fair value analysis →

Notify me when 1672 reaches fair value

Put 1672 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 51 · Market factors (momentum, volatility) 21

Profitability 0
Margins and returns on capital today
Quality Growth 54
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 13
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+58.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−66.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−43.4%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−620.3% (2020) → −23,853.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

1672 screens 390% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Ascletis Pharma Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 51 · Above median
Fair Value upside −83% · Bottom 25%
Profitability
Return on assets −14% · Below median
Net margin (TTM) 0% · Below median
Growth and dividend
Revenue growth −26% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.76× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.63 $566.09 +10%
Regeneron Pharmaceuticals, Inc REGN $774.11 $1,241 +60%
argenx SE ARGX $984.39 $917.18 −7%
BeOne Medicines AG 688235 ¥247.30 ¥124.62 −50%
Samsung Biologics Co 207940 1,415,000 KRW 1,556,500 KRW +10%
CSL Limited CSL A$174.41 A$191.85 +10%
Alnylam Pharmaceuticals, Inc ALNY $238.27 $211.88 −11%
Royalty Pharma plc RPRX $58.61 $24.22 −59%
Celltrion, Inc 068270 178,200 KRW 74,519 KRW −58%
BioNTech SE BNTX $96.69 $62.63 −35%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ascletis Pharma Inc · Fair Value
HK$1.68 −390%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Ascletis Pharma Inc Fair Value". https://www.fairvalue-calculator.com/stock/1672

Frequently asked questions

Is Ascletis Pharma Inc (1672) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of HK$1.68 versus a price of HK$8.24, about −80% upside (overvalued).
What is the fair value of 1672?
Our model-based fair value for Ascletis Pharma Inc is HK$1.68 (as of Sep 13, 2026), built from audited fundamentals. The current price: HK$8.24.
What is the quality score of 1672?
Ascletis Pharma Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ascletis Pharma Inc (1672)?
Our model-based price target is the fair value of HK$1.68 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario HK$1.11, optimistic scenario HK$2.10. It is a calculation from audited fundamentals, not an analyst target.
What is the Ascletis Pharma Inc stock forecast for 2026?
Our models put fair value at HK$1.68, about −80% upside versus a price of HK$8.24 (overvalued). Cautious scenario HK$1.11, optimistic scenario HK$2.10. The calculation is refreshed regularly with new filings.
What is the revenue of Ascletis Pharma Inc (1672)?
Ascletis Pharma Inc reported trailing-twelve-month revenue of about HK$2.0M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Ascletis Pharma Inc (1672)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ascletis Pharma Inc it is HK$1.68 per share (as of Sep 13, 2026), against a price of HK$8.24. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Ascletis Pharma Inc stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 1672 trades above its calculated fair value: price HK$8.24, fair value HK$1.68, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1672?
No. The price is what the market pays today (HK$8.24); the fair value is what the company's own numbers justify (HK$1.68). For Ascletis Pharma Inc the two are HK$6.56 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ascletis Pharma Inc worth?
The market values Ascletis Pharma Inc at about HK$11.5B (market capitalisation, as of Sep 13, 2026). Per share that is HK$8.24; our models calculate a fair value of HK$1.68 per share.
What do the bullish and bearish scenarios say about 1672?
Our models span a range for Ascletis Pharma Inc: cautious scenario HK$1.11, base HK$1.68, optimistic HK$2.10 per share (as of Sep 13, 2026, price HK$8.24). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ascletis Pharma Inc (1672)?
Balance-sheet figures for Ascletis Pharma Inc (as of Sep 13, 2026): return on equity −18.5%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 1672 from its 52-week high?
Ascletis Pharma Inc trades at HK$8.24, about 59% below its 52-week high of HK$19.86 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.68 is for.
Which stocks are comparable to Ascletis Pharma Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ascletis Pharma Inc stock attractive at the current price?
The data as of Sep 13, 2026: price HK$8.24, calculated fair value HK$1.68 (−80%), Quality Score 49/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1672 calculated?
We run Ascletis Pharma Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.68, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. Ascletis Pharma Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ascletis Pharma Inc (1672)?
The closing price on Sep 16, 2026 was HK$8.24. Our model-based fair value is HK$1.68, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ascletis Pharma Inc right now?
The price sits above even our optimistic bull case (HK$2.10). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$1.11 to HK$2.10) leaves room in how you read the outcome.

Key figures of Ascletis Pharma Inc

How large is the market capitalisation of Ascletis Pharma Inc (1672)?
The market capitalisation of Ascletis Pharma Inc is HK$11.5B (≈ $1.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Ascletis Pharma Inc (1672)?
Earnings per share at Ascletis Pharma Inc are HK$−0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Ascletis Pharma Inc (1672)?
The return on equity (ROE) of Ascletis Pharma Inc is −18.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ascletis Pharma Inc (1672)?
On an EBIT basis the return on assets of Ascletis Pharma Inc is −14.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ascletis Pharma Inc (1672)?
The operating margin of Ascletis Pharma Inc is −31,064% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ascletis Pharma Inc (1672)?
Revenue at Ascletis Pharma Inc is growing −26.2% versus a year earlier (3y avg −66.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ascletis Pharma Inc (1672) generate?
The free cash flow of Ascletis Pharma Inc is −HK$331M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Ascletis Pharma Inc (1672) hold?
Ascletis Pharma Inc holds more cash than debt, HK$1.4B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Ascletis Pharma Inc in the live analysis

One click puts Ascletis Pharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.